Altered expression of histone deacetylases in cancer

Area of Science:

• Oncology
• Epigenetics
• Molecular Biology

Background:

• Epigenetic alterations, particularly histone deacetylation, are frequently observed in cancer.
• Histone deacetylases (HDACs) are implicated in tumorigenesis and are actively explored as therapeutic targets.
• Sirtuins (class III HDACs) are gaining attention as potential cancer biomarkers and therapeutic agents.

Purpose of the Study:

• To review the link between HDAC deregulation and cancer promotion.
• To highlight advancements in HDAC inhibitor therapy for neoplastic diseases, especially urological cancers.
• To discuss the dual role of sirtuins in tumor development and targeted therapies.

Main Methods:

• Literature review of epigenetic mechanisms in cancer.
• Analysis of current research on HDAC inhibitors in preclinical and clinical settings.
• Focus on sirtuin function and therapeutic targeting strategies.

Main Results:

• HDAC deregulation is associated with cancer progression.
• HDAC inhibitors show therapeutic potential, particularly in urological malignancies.
• Sirtuins exhibit complex roles in cancer, offering both challenges and opportunities for treatment.

Conclusions:

• HDAC inhibitors represent a promising therapeutic avenue for cancer treatment.
• Targeting sirtuins requires a nuanced approach due to their multifaceted roles.
• Further research is needed to translate HDAC-targeted therapies into effective clinical practice.